
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 19, 2024, titled "Aurobindo Pharma receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray 50 mcg/spray ".
Filed with NSE ·

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 19, 2024, titled "Aurobindo Pharma receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray 50 mcg/spray ".
6ix hasn’t read this filing yet.
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma